Industry
Receptor Life Sciences
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
Failure Rate
100.0%
2 terminated/withdrawn out of 2 trials
Success Rate
0.0%
-86.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
2(100.0%)
2Total
Phase 1(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT05678881Phase 1Terminated
Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy
Role: lead
NCT05429788Phase 1Withdrawn
Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
Role: lead
All 2 trials loaded